Experimental comparative study on myelotoxicity of 4'-deoxy-4'-I-doxorubicin and of doxorubicin.
4'-Deoxy-4'-I-doxorubicin (I-Dx) is 1.5-2 times more potent than doxorubicin (Dx) on some mice tumors and does not seem to be cardiotoxic. A comparison was made of the effects of both anthracyclines on mice bone marrow hemopoietic progenitors (CFU-S, GM-CFC) and peripheral blood cells. The experimental model is based on dose survival and time survival curves following single or repeated (1 weekly administration for 4 weeks) doses. Results indicate slightly higher sensitivity of assayed populations to I-DX than to Dx.
Lerza
R
R
Istituto Scientifico di Medicina Interna, Università di Genova, Italia.
Bogliolo
G
G
Mencoboni
M
M
Saviane
A
A
Muzzulini
C
C
Pannacciulli
I
I
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity*; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D012156:Reticulocytes / Q000187:drug effects
D004317:Doxorubicin; C030851:esorubicin